MX2013010530A - Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata. - Google Patents
Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata.Info
- Publication number
- MX2013010530A MX2013010530A MX2013010530A MX2013010530A MX2013010530A MX 2013010530 A MX2013010530 A MX 2013010530A MX 2013010530 A MX2013010530 A MX 2013010530A MX 2013010530 A MX2013010530 A MX 2013010530A MX 2013010530 A MX2013010530 A MX 2013010530A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- prostate cancer
- receptor antagonist
- androgen receptor
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe un método para tratar un sujeto mamífero que padece de cáncer de próstata que comprende i) un oligonucleótido que reduce la expresión de clusterina y ii) un antagonista del receptor de andrógeno que tiene la estructura (Ver Formula) o una sal farmacéuticamente aceptable del mismo, cada uno en una cantidad que cuando en combinación con el otro es efectivo para tratar el sujeto mamífero.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161452583P | 2011-03-14 | 2011-03-14 | |
US201161453309P | 2011-03-16 | 2011-03-16 | |
US201161453885P | 2011-03-17 | 2011-03-17 | |
US201161493336P | 2011-06-03 | 2011-06-03 | |
PCT/IB2012/000609 WO2012123820A1 (en) | 2011-03-14 | 2012-03-14 | Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013010530A true MX2013010530A (es) | 2014-05-01 |
Family
ID=46830100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013010530A MX2013010530A (es) | 2011-03-14 | 2012-03-14 | Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140088178A1 (es) |
EP (1) | EP2685989A4 (es) |
JP (1) | JP2014509607A (es) |
KR (1) | KR20140048106A (es) |
AU (1) | AU2012228007B2 (es) |
CA (1) | CA2830191A1 (es) |
IL (1) | IL227718A0 (es) |
MX (1) | MX2013010530A (es) |
RU (1) | RU2013145551A (es) |
SG (1) | SG192952A1 (es) |
WO (1) | WO2012123820A1 (es) |
ZA (1) | ZA201307558B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1163254T3 (da) | 1999-02-26 | 2008-06-09 | Univ British Columbia | TRPM-2 antisense-behandling |
US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
AU2012228010B2 (en) | 2011-03-15 | 2016-08-25 | The University Of British Columbia | Combination of anti-clusterin oligonucleotide with Hsp90 inhibitor for the treatment of prostate cancer |
CN106442992A (zh) * | 2016-08-03 | 2017-02-22 | 上海延安药业有限公司 | 阿比特龙衍生物的药代动力学评估方法 |
CA3138197A1 (en) * | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
JP2022542013A (ja) | 2019-07-25 | 2022-09-29 | フィリップ・モーリス・プロダクツ・ソシエテ・アノニム | エアロゾル発生物品のための自動販売装置 |
EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
US11834458B2 (en) | 2021-03-23 | 2023-12-05 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005094899A1 (en) * | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
CA2753425A1 (en) * | 2009-02-24 | 2010-09-02 | Medivation Prostate Therapeutics, Inc. | Specific diarylhydantoin and diarylthiohydantoin compounds |
-
2012
- 2012-03-14 MX MX2013010530A patent/MX2013010530A/es unknown
- 2012-03-14 AU AU2012228007A patent/AU2012228007B2/en not_active Expired - Fee Related
- 2012-03-14 RU RU2013145551/15A patent/RU2013145551A/ru not_active Application Discontinuation
- 2012-03-14 KR KR1020137027108A patent/KR20140048106A/ko not_active Application Discontinuation
- 2012-03-14 EP EP12757052.1A patent/EP2685989A4/en not_active Withdrawn
- 2012-03-14 CA CA2830191A patent/CA2830191A1/en not_active Abandoned
- 2012-03-14 US US14/005,179 patent/US20140088178A1/en not_active Abandoned
- 2012-03-14 JP JP2013558526A patent/JP2014509607A/ja active Pending
- 2012-03-14 WO PCT/IB2012/000609 patent/WO2012123820A1/en active Application Filing
- 2012-03-14 SG SG2013064464A patent/SG192952A1/en unknown
-
2013
- 2013-09-16 IL IL227718A patent/IL227718A0/en unknown
- 2013-10-10 ZA ZA2013/07558A patent/ZA201307558B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201307558B (en) | 2015-08-26 |
AU2012228007B2 (en) | 2016-09-08 |
US20140088178A1 (en) | 2014-03-27 |
SG192952A1 (en) | 2013-09-30 |
IL227718A0 (en) | 2013-09-30 |
CA2830191A1 (en) | 2012-09-20 |
RU2013145551A (ru) | 2015-04-20 |
AU2012228007A1 (en) | 2013-10-31 |
NZ616465A (en) | 2015-08-28 |
KR20140048106A (ko) | 2014-04-23 |
JP2014509607A (ja) | 2014-04-21 |
WO2012123820A1 (en) | 2012-09-20 |
EP2685989A4 (en) | 2014-12-10 |
EP2685989A1 (en) | 2014-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013010530A (es) | Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata. | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2020004689A (es) | Tratamiento del cancer con inhibidores de tor cinasa. | |
PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
BR112013021318A2 (pt) | vetor e método de tratar ou prevenir coroideremia em um paciente com necessidade do mesmo | |
WO2013056148A3 (en) | Scd1 antagonists for treating cancer | |
EP2616144A4 (en) | PHOTODYNAMIC THERAPY SYSTEM, DEVICE AND PROCESSING METHOD THEREOF | |
MX2015013177A (es) | Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki. | |
PH12014502047B1 (en) | Treatment of cancer with tor kinase inhibitors | |
PH12014502046B1 (en) | Treatment of cancer with tor kinase inhibitors | |
MX360774B (es) | Antagonistas de progesterona. | |
PH12015502342A1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
MX2019010098A (es) | Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico. | |
PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
MX2015011386A (es) | Metodo para tratar cancer pancreatico. | |
MX2015011671A (es) | Co-administracion de esteroides y acido zoledronico para prevenir y tratar la osteoartritis. | |
MX2013010524A (es) | Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata. | |
AU2012346899A8 (en) | Materials and methods related to NSAID chemoprevention in colorectal cancer | |
MX350868B (es) | Medicamentos y metodos para tratar cancer. | |
WO2011128434A3 (en) | Treatment of endocrine resistant breast cancer | |
WO2013040504A3 (en) | Srpx for treatment of cancer |